Analyzing PURE Bioscience (OTCMKTS:PURE) and Apyx Medical (NASDAQ:APYX)

Apyx Medical (NASDAQ:APYX) and PURE Bioscience (OTCMKTS:PURE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Profitability

This table compares Apyx Medical and PURE Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-21.22%	-114.95%	-18.49%
PURE Bioscience	-108.77%	N/A	-356.86%

Risk and Volatility

Apyx Medical has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, PURE Bioscience has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Apyx Medical and PURE Bioscience, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1	1	3	1	2.67
PURE Bioscience	0	0	0	0	0.00

Apyx Medical presently has a consensus target price of $6.50, suggesting a potential upside of 82.58%. Given Apyx Medical’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Apyx Medical is more favorable than PURE Bioscience.

Valuation & Earnings

This table compares Apyx Medical and PURE Bioscience”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$52.84 million	2.82	-$11.21 million	($0.27)	-13.19
PURE Bioscience	$2.20 million	3.33	-$2.40 million	($0.03)	-2.18

PURE Bioscience has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than PURE Bioscience, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

55.3% of Apyx Medical shares are held by institutional investors. 15.2% of Apyx Medical shares are held by insiders. Comparatively, 35.6% of PURE Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Apyx Medical beats PURE Bioscience on 9 of the 15 factors compared between the two stocks.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

About PURE Bioscience

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.